Treatment of acute myeloid leukemia in children: A practical perspective
- PMID: 33844444
- DOI: 10.1002/pbc.28979
Treatment of acute myeloid leukemia in children: A practical perspective
Abstract
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease that requires a multifaceted treatment approach. Although outcomes for low-risk AML have improved significantly over recent decades, high-risk AML continues to be associated with an adverse prognosis. Recent advances in molecular diagnostics, risk stratification, and supportive care have contributed to improvements in outcomes in pediatric AML. Targeted approaches, for example, the use of tyrosine kinase inhibitors to treat FLT3-ITD AML, offer promise and are currently undergoing clinical investigation in pediatric patients. New approaches to hematopoietic stem cell transplantation, including the use of haploidentical donors, are significantly expanding donor options for patients with high-risk AML. This review provides an overview of recent advances in the treatment of pediatric AML that are likely to have clinical impact and reshape the standard of care.
Keywords: HSCT; acute myeloid leukemia; childhood AML; pediatric AML.
© 2021 Wiley Periodicals LLC.
Similar articles
-
The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.Hematology. 2021 Dec;26(1):179-185. doi: 10.1080/16078454.2021.1880753. Hematology. 2021. PMID: 33594943
-
Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.Eur J Haematol. 2016 Mar;96(3):236-44. doi: 10.1111/ejh.12575. Epub 2015 May 18. Eur J Haematol. 2016. PMID: 25912052
-
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.Pediatr Blood Cancer. 2015 Jun;62(6):1048-54. doi: 10.1002/pbc.25437. Epub 2015 Feb 8. Pediatr Blood Cancer. 2015. PMID: 25662999
-
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.Biol Blood Marrow Transplant. 2016 Jun;22(6):982-990. doi: 10.1016/j.bbmt.2016.01.013. Epub 2016 Jan 16. Biol Blood Marrow Transplant. 2016. PMID: 26785334 Review.
-
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.Expert Rev Hematol. 2014 Apr;7(2):301-15. doi: 10.1586/17474086.2014.857596. Epub 2013 Dec 6. Expert Rev Hematol. 2014. PMID: 24308526 Review.
Cited by
-
Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia.Oncotarget. 2021 Jul 6;12(14):1377-1387. doi: 10.18632/oncotarget.28000. eCollection 2021 Jul 6. Oncotarget. 2021. PMID: 34262648 Free PMC article.
-
Genomic alterations in a cohort of pediatric acute myeloid leukemia patients at two cancer centers in Colombia.Int J Hematol. 2023 Feb;117(2):269-277. doi: 10.1007/s12185-022-03475-w. Epub 2022 Oct 24. Int J Hematol. 2023. PMID: 36279042 Free PMC article.
-
Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia.Bone Marrow Transplant. 2024 Jun;59(6):824-831. doi: 10.1038/s41409-024-02214-5. Epub 2024 Mar 5. Bone Marrow Transplant. 2024. PMID: 38443705
-
The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children's Leukemia Group-AML 2015 Study.Transl Pediatr. 2024 Feb 29;13(2):376-379. doi: 10.21037/tp-23-536. Epub 2024 Feb 23. Transl Pediatr. 2024. PMID: 38455741 Free PMC article. No abstract available.
-
Deciphering Selectivity Mechanism of BRD9 and TAF1(2) toward Inhibitors Based on Multiple Short Molecular Dynamics Simulations and MM-GBSA Calculations.Molecules. 2023 Mar 12;28(6):2583. doi: 10.3390/molecules28062583. Molecules. 2023. PMID: 36985555 Free PMC article.
References
REFERENCES
-
- Smith M, Gloeckler Ries LA, Gurney JG, Ross JA. Leukemia. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
-
- Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-1669.
-
- Gibson BES, Sauer MG, Amrolia P. Acute myeloid leukemia in children. In: Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT Handbook. Springer International Publishing; 2019:523-530.
-
- Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;119(25):5980-5988.
-
- Klein K, Kaspers G, Harrison CJ, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2015;33(36):4247-4258.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous